- Home
- SRPT
as 05-30-2025 4:00pm EST
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
| Founded: | 1980 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | N/A | IPO Year: | 1997 |
| Target Price: | $125.43 | AVG Volume (30 days): | 5.9M |
| Analyst Decision: | Buy | Number of Analysts: | 23 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $34.10 - $173.25 | Next Earning Date: | 05-06-2025 |
| Revenue: | $2,233,371,000 | Revenue Growth: | 59.15% |
| Revenue Growth (this year): | 39.01% | Revenue Growth (next year): | 13.35% |
Stock Insider Trading Activity of Sarepta Therapeutics Inc. (DE) (SRPT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Nicaise Claude | SRPT | Director | Mar 12 '25 | Sell | $99.64 | 2,491 | $248,203.24 | 27,812 |
Latest Sarepta Therapeutics Inc. (DE) News
SRPT Breaking Stock News: Dive into SRPT Ticker-Specific Updates for Smart Investing
StockStory
2 days ago
1 Volatile Stock to Own for Decades and 2 to Keep Off Your Radar
Insider Monkey
4 days ago
Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)?
BioPharma Dive
10 days ago
FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study
Simply Wall St.
10 days ago
Sarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne
MT Newswires
10 days ago
Sarepta Therapeutics Says Dosing to Continue in UK Trial of Duchenne Muscular Dystrophy Treatment
Business Wire
11 days ago
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
Simply Wall St.
11 days ago
High Growth Tech Stocks In The US Market To Watch
Simply Wall St.
12 days ago
3 Stocks Investors May Be Undervaluing By Up To 43.5%
Compare SRPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRPT Sarepta Therapeutics Inc. (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.